The company remains a pre-commercial entity with zero revenue and consistent operating losses, which reached $5.2 million in 2026Q1.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 18.71M | 16.7M | 16.16M | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.4M | 16.6M | 1.19M | 688.56K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.74B | 6.8B | 3.16M | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 11.75M | 9.9B | 13.01M | 5.6M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 935.32K | 280.36K | 101.49K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -1M | -16.69B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.5M | 0 | 0 |
| Operating Income | -18.71M | -16.7M | -16.16M | -8.83M | -10.54M | -9.13M | -6.51M | -4.32M | -3.4M | -16.6M | -1.19M | -689K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -3.36% | -83.01% | 16.19% | -15.44% | -40.23% | -50.54% | -27.06% | 79.5% | -1291.9% | -73.12% | - |
| EBITDA | -17.93M | -16.7M | -16.16M | -8.83M | -10.54M | -9.13M | 0 | -4.22M | -72K | -14.5M | 0 | -438 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -3.98% | -3.36% | -83.01% | 16.19% | -15.44% | - | 100% | -5767.88% | 99.5% | - | 100% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 6.51M | 0 | 3.33M | 2.1M | 1.19M | 688.56K |
| EBIT | -17.93M | -16.7M | -16.16M | -8.83M | -10.54M | -9.13M | -6.51M | -4.22M | -3.33M | -16.55M | -1.18M | -687K |
| Net Interest Income | 3.72M | 2.99M | 404.02K | 429.04K | 21.24K | 24.02K | 81.9K | 98.89K | 0 | 0 | 0 | 0 |
| Interest Income | 3.72M | 2.99M | 404.02K | 429.04K | 21.24K | 24.02K | 81.9K | 98.89K | 103.22K | 48.26K | 7.23K | 1.25K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103.22K | 48.26K | 7.23K | 0 |
| Other Income/Expense | 3.72M | 2.99M | 575.3K | 429.04K | 21.24K | 24.02K | 204.3K | 98.89K | 31.15K | 48.26K | 7.23K | 1.25K |
| Pretax Income | -14.98M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M | -4.22M | -3.3M | -16.55M | -1.18M | -687K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -71.61K | 0 | 800 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2.17% | 0% | -0.07% | 0% |
| Net Income | -14.98M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M | -4.22M | -3.23M | -16.55M | -1.19M | -687K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 9.57% | 11.99% | -85.5% | 20.1% | -15.52% | -44.39% | -49.23% | -30.88% | 80.5% | -1296.34% | -72.58% | - |
| Net Income (Continuing) | -14.98M | -13.72M | -15.59M | -8.4M | -10.52M | -9.1M | -6.3M | -4.22M | -3.23M | -16.55M | -1.19M | -687K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.76 | -1.85 | -1.36 | -0.58 | -0.83 | -0.73 | -0.58 | -0.40 | -0.31 | -1.59 | -0.12 | -0.08 |
| EPS Growth % | -30.19% | -36.03% | -134.48% | 30.12% | -13.7% | -25.86% | -45% | -29.03% | 80.5% | -1225% | -42.52% | - |
| EPS (Basic) | - | -1.85 | -1.36 | -0.58 | -0.83 | -0.73 | -0.58 | -0.40 | -0.31 | -1.59 | -0.12 | -0.08 |
| Diluted Shares Outstanding | 8.54M | 7.41M | 11.48M | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 9.86M | 8.16M |
| Basic Shares Outstanding | 8.54M | 7.41M | 11.44M | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 9.85M | 8.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |
Clinical trial binary outcomes
As indicated by recent financial disclosures, Monopar’s quarterly R&D expenditures have fluctuated significantly, peaking at $9.9 million in 2024Q4 before moderating to $3.5 million in 2026Q1, reflecting the episodic nature of clinical trial milestones and the company's reliance on external research partnerships for its oncology pipeline.
The volatility in R&D spending suggests that the company’s cost structure is highly sensitive to the timing of specific clinical trial phases rather than a steady-state operational burn. Investors should monitor whether the recent moderation in spending represents a strategic efficiency gain or merely a temporary lull between major trial enrollment periods.
Based on reported income statements, Monopar continues to operate as a pure research entity with zero revenue, resulting in consistent operating losses that reached $5.2 million in 2026Q1, underscoring the lack of scalable operating leverage inherent in a pre-commercial biotechnology firm at this stage of development.
The absence of revenue means that every dollar of SG&A and R&D expense directly impacts the bottom line without any offsetting gross profit contribution. The company’s ability to manage its operating loss is entirely dependent on its capacity to control administrative overhead while simultaneously funding high-cost clinical development programs.
According to historical data, Monopar has utilized stock-based compensation to manage cash outflows, with quarterly charges reaching as high as $1.4 million in 2025Q1, which effectively masks the true cash-based operational burn rate and dilutes existing shareholders to preserve the company's $61.8 million cash position.
While non-cash compensation helps conserve liquidity, it represents a significant hidden cost that investors must account for when evaluating the company's long-term capital requirements. The reliance on equity-based incentives suggests that management is prioritizing cash preservation over minimizing dilution, a common but risky trade-off for clinical-stage firms.
While the company maintains a debt-free balance sheet, the lack of revenue generation, as evidenced by the historical income statement data, suggests that the firm remains entirely vulnerable to clinical trial failures that could render its current $61.8 million cash runway insufficient for long-term survival.
Short-term observers might focus on the company's disciplined expense management, but the fundamental risk remains the binary nature of its pipeline assets. If the primary clinical programs fail to meet efficacy endpoints, the company’s current cost structure will provide little protection against a rapid loss of market valuation and potential financing difficulties.
Quick answers to the most common questions about buying MNPR stock.
For fiscal year 2025, Monopar Therapeutics Inc. (MNPR) reported total revenue of $0.0M.
Monopar Therapeutics Inc. (MNPR) reported a net loss of $13.7M for the fiscal year ending 2025.